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Background: Microwave ablation (MWA) is increasingly utilized in the treatment of hepatic tumours.
Promising single-centre reports have demonstrated its safety and efficacy, but this modality has not been
studied in a prospective, multicentre study.
Methods: Eighteen international centres recorded operative and perioperative data for patients under-
going MWA for tumours of any origin in a voluntary Internet-based database. All patients underwent
operative MWA using a 2.45-GHz generator with a 5-mm antenna.
Results: Of the 140 patients, 114 (81.4%) were treated with MWA alone and 26 (18.6%) were treated
with MWA combined with resection. Multiple tumours were treated with MWA in 40.0% of patients. A total
of 299 tumours were treated in these 140 patients. The median size of ablated lesions was 2.5 cm (range:
0.5–9.5 cm). Tumours were treated with a median of one application (range: 1–6 applications) for a median
of 4 min (range: 0.5–30.0 min). A power setting of 100 W was used in 78.9% of cases. Major morbidity
was 8.3% and in-hospital mortality was 1.9%.
Conclusions: These multi-institution data demonstrate rapid ablation time and low morbidity and
mortality rates in patients undergoing operative MWA with a high rate of multiple ablations and concomi-
tant hepatic resection. Longterm follow-up will be required to determine the efficacy of MWA relative to
other forms of ablative therapy.
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Introduction
Microwave ablation (MWA) represents the newest generation of
thermal ablation technologies; it is increasingly utilized in the
treatment of primary and metastatic hepatic malignancies and a
variety of MWA systems are now clinically available. Microwave
technology utilizes energy at frequencies ranging from 915 MHz
to 9.2 GHz and differs from other thermal ablation modalities,
most notably radiofrequency ablation (RFA), in many key
aspects.1
Radiofrequency ablation requires a closed circuit between the
ablation probe and the grounding pad for the flow of electrical
current; therefore, RFA is subject to the distortion of the ablation
zone when this current follows the path of least resistance, as well
as increased tissue impedance if the tissue is heated too rapidly or
to > 100 °C because the tissue chars and/or the tissue water boils.1
Radiofrequency ablation also appears susceptible to ‘heat sink’
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whereby thermal energy is diverted from the target tissue by the
flow of blood through adjacent vessels.2–5 Microwave ablation
does not rely on the flow of current; rather, it causes coagulative
necrosis by generating an electromagnetic field inside which a
rapid and homogeneous heating of tissue occurs.6 The ablation of
tissue within this field is not subject to the same limitations as
RFA; however, outside the microwave near field, heat from the
ablation zone is conducted through the surrounding tissue in a
fashion similar to that seen in RFA, and the heat sink effect is
apparent. In combination, these different properties of MWA
allow a larger, more homogeneous and more predictable ablation
zone to be accomplished in a shorter period of time. Microwave
technology also allows for the simultaneous treatment of multiple
tumours, in which RFA is technically limited.
Despite its apparent advantages, MWA is still a relatively new
ablative modality and current clinical trials consist of single-
institution case series, albeit with promising results.7–11 Moreover,
new MWA technology is rapidly becoming available for clinical
use, and each new combination of generator and ablation antenna
cannot be presumed to provide equivalent results. Therefore, it is
increasingly important that clinical validation models are in place
as technological innovation in this field progresses. One method
of resolving this challenge is to design a multicentre prospective
database that facilitates patient enrolment and provides a plat-
form from which to critically evaluate a new surgical modality
based on its complication profile and efficacy.12
Current MWA technology uses frequencies between 915 MHz
and 9.2 GHz. The first reported open surgical MWA was per-
formed in Japan over two decades ago using a 2.45-GHz system
(Microtaze; Heiwa Electronic Industrial Co. Ltd, Osaka, Japan).13
This frequency has been in use in Europe and Asia since the 1990s.
By contrast, microwave technology was first used in the USA in
2003 and involved a 915-MHz system (Vivant Medical, Inc.,
Mountain View, CA, USA).14 Both 915-MHz and 2.45-GHz
systems are now employed in the USA.
The focus of this international database was the evaluation of
the safety and efficacy of MWA performed using the commercially
available 2.45-GHz Acculis V generator with a 5-mm antenna
(Acculis Ltd/Microsulis Medical Ltd, Denmead, UK) during open
or laparoscopic operations.
Materials and methods
A secure Internet-based database was created in which
de-identified data on MWAs could be voluntarily and indepen-
dently recorded. All ablations were performed using the commer-
cially available Microsulis 2.45-GHz Acculis V generator with a
5-mm antenna (Fig. 1). Thirty-six centres originally enrolled for
participation in this study; however, data were recorded at the 18
international centres listed in Table 1. Patients with hepatic
tumours (primary or metastatic) treated with this 2.45-GHz
MWA system were enrolled between January 2008 and March
2010. Each centre adhered to the specific policies mandated by the
institutional review board of its respective institution. The data-
base website consisted of four separate data entry sections for the
following categories of information: indications for ablation;
operative data; morbidity and mortality, and recurrence and
follow-up. Data input included indications for ablation (tumour
aetiology) and operative variables (type of treatment, ablation
power setting, duration of application, number of applications,
lesion diameter). Outcome variables included major and minor
complications, as well as in-hospital, 30-day and 90-day mortality
rates. Follow-up data included length of follow-up and recurrence
as identified by post-ablation radiological imaging consisting of
either magnetic resonance imaging (MRI) or computed tomog-
raphy (CT) according to the standard of the particular institution.
Recurrence was categorized according to the site at which it
occurred: Local recurrence was defined as viable tumour at the
previous ablation site noted on follow-up and incomplete ablation
was represented by residual tumour at the ablation zone discov-
ered on the first post-treatment radiological imaging. Regional
recurrence was defined as the appearance of a new lesion in the
liver located at a site distinct from the ablation site.
Descriptive statistics (tumour size, number of applications/
lesions, duration of application, follow-up, mortality and recur-
rence) were compared. sas Version 9.2 (SAS Institute, Inc., Cary,
NC, USA) was used for analysis. A P-value of <0.05 was consid-
ered to indicate statistical significance.
Results
A total of 162 patients were enrolled in the database. Data on
indications for ablation were recorded for 126 patients, complete
operative details were recorded for 140 patients, morbidity and
Figure 1 (A) The 2.45-GHz generator and (B) 5-mm antenna
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mortality were recorded for 117 patients, and follow-up imaging
data were recorded for 83 patients. In order to appropriately assess
this 2.45-GHz generator with 5-mm antenna MWA system, only
the 140 patients for whom complete operative details were avail-
able were included in this analysis.
Tumour aetiology was recorded for 111 of these 140 patients
(Table 2). Colorectal hepatic metastases (CRHM) represented the
most prevalent aetiology (50.5%). The CRHM group demon-
strated a median tumour size of 2.0 cm (mean: 2.27 cm; range:
0.3–7.0 cm) and a median of two tumours per patient (mean:
2.82; range: 1–8 tumours). The second most prevalent aetiology
(34.2%) was hepatocellular carcinoma (HCC). In the HCC group,
median tumour size was 2.8 cm (mean: 3.16 cm; range: 0.5–
7.0 cm) and patients demonstrated a median of one tumour each
(mean: 1.45; range: 1–6 tumours).
Microwave ablation alone was performed in 114 patients
(81.4%) who exhibited a median of one tumour per patient
(mean: 2.14; range: 1–9 tumours). Of these, 56 patients under-
went multiple ablations performed for separate lesions; these con-
stituted 40.0% of all patients and 49.1% of patients undergoing
ablation alone. Twenty-one patients (15.0%) were treated with
MWA and concomitant resection of separate lesions. Three
patients (2.1%) were treated with a combination of MWA and
resection of the same lesion and two patients (1.4%) were treated
with a combination of ablation, resection and combined ablation/
resection of multiple lesions.
A total of 299 individual tumours were treated in these 140
patients, of which 247 (82.6%) were treated with ablation alone,
47 (15.7%) were treated with resection alone and five (1.7%) were
treated with combined ablation and resection. The median diam-
eter of those tumours treated with ablation alone was 2.5 cm
(mean: 2.7 cm; range: 0.5–9.5 cm), whereas the median diameter
of resected tumours was 1.2 cm (mean: 2.1 cm; range: 0.3–
9.0 cm). The median number of applications per tumour was 1.0
(mean: 1.59; range: 1–6 applications); 125 tumours (50.6%) were
treated with only one application and another 63 tumours
(25.5%) were treated with two applications. Of the 247 ablations,
195 (78.9%) were performed using the standard 100-W energy
setting, and the median total ablation time per tumour was 4 min
(mean: 5.25 min; range: 0.5–30 min). A comparison of energy
deposition per tumour ablation (power ¥ duration) with the
diameter of the lesions demonstrated a significant increase in
energy deposition with increasing tumour diameter (P < 0.0001)
(Fig. 2).
Morbidity data were available for 108 (77.1%) of the 140
patients, of whom 15 underwent concomitant liver resection and
93 underwent ablation alone (Table 3). Median length of stay was
4 days (range: 0–100 days). Twenty-four individual complications
were noted, of which 11 were considered major and 13 were
minor. Nineteen patients (17.6%) experienced at least one com-
plication, and nine of these patients (8.3%) experienced at least
one major complication. Five of the 15 patients (33.3%) who
underwent concomitant liver resection and 14 of the 93 patients
Table 1 Institutions contributing patient data to the study database (n = 18)
Leicester Royal Infirmary, Leicester, UK Jersey Shore Hospital, Jersey Shore, NJ, USA
North Manchester General Hospital, Manchester, UK Hospital Beaujon, Paris, France
North Hampshire Hospital, Basingstoke, UK Bern University Hospital, Bern, Switzerland
Mater Hospital, Belfast, UK Agia Olga Hospital, Athens, Greece
Johns Hopkins University Hospital, Baltimore, MD, USA Haut Pierre Hospital, Strasbourg, France
Renown Regional Medical Center, Reno, NV, USA University Hospital Groningen, Groningen, the Netherlands
Hospital of Saint Raphael, New Haven, CT, USA McCallum Cancer Centre, Melbourne, Vic, Australia
Roger Williams Cancer Center, Providence, RI, USA Prince of Wales Hospital, Hong Kong SAR, China
Carolinas Medical Center, Charlotte, NC, USA Canberra Hospital, Canberra, ACT, Australia
Table 2 Diagnoses of patients treated with microwave ablation
Aetiology Patients, n (%)
Colorectal hepatic metastases 56 (50.5%)
Hepatocellular carcinoma 38 (34.2%)
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Figure 2 Correlation between energy deposition and tumour
diameter
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(15.1%) who underwent MWA alone experienced at least one
complication.
Two of these 108 patients (1.9%) died while in hospital. In the
total sample of 140 patients, 30- and 90-day mortality data were
recorded for only 86 (61.4%) and 79 (56.4%) patients, respec-
tively. Based on this limited data accrual, 30- and 90-day mortality
rates were found to be 2.3% (n = 2) and 5.1% (n = 4), respectively.
Follow-up imaging data were recorded for 68 (48.6%) of the
140 patients for whom operative data were available. The median
follow-up was 4 months (mean: 5.9 months; range: 0.5–
21 months). Two patients (2.9%) were found to have incomplete
ablations on the first follow-up radiological imaging. Hepatic
recurrence was noted in 24 of these patients over this limited
follow-up period; seven of these patients were noted to have local
recurrence alone, eight were noted to have regional recurrence
alone and two were found to have both local and regional recur-
rence. In seven patients, hepatic recurrence was noted; however, its
relationship with the original ablation site was not detailed
adequately, which makes the true incidence of local recurrence
indeterminate.
Discussion
Hepatic resection and, in select patients, liver transplantation rep-
resent the standard treatments for primary liver tumours and
hepatic resection is considered the standard treatment modality
for patients with an increasing range of hepatic metastases. Mul-
tiple advances over the previous 30 years have expanded the indi-
cations for hepatic resection; however, despite these advances,
many patients still do not meet criteria for resection or transplan-
tation.15,16 Tumour-related issues such as tumour location and
size, and extrahepatic disease, as well as patient-related concerns
such as advanced underlying liver dysfunction and comorbid con-
ditions, often preclude resection. For these patients, ablation pro-
vides a less morbid yet still potentially curative treatment option.17
In select patients with early HCC and cirrhosis, multiple large
case series have demonstrated low perioperative morbidity and
exceptional longterm outcomes with thermal ablation, of which
RFA is the most utilized and studied ablative modality.18–21 With
improving ablative options, some authors have even advocated the
application of thermal ablation rather than hepatic resection in
select patients. Two randomized controlled trials in patients with
resectable early HCC with preserved hepatic function showed no
survival difference between hepatic resection and RFA;22,23
however, study design issues in these trials have left the issue of
equivalence in this highly selected patient population open to
debate.24
Similarly, resection is the standard treatment for resectable
CRHM; however, ablation is now routinely employed as one
aspect of a multimodal, often staged, treatment algorithm aimed
Table 3 Morbidity data for the 19 patients who experienced at least one complication following hepatic microwave ablation administered
alone or in combination with hepatic resection
Patient Diagnosis Tumour treatment Complication Mortality
Resection, n Ablation, n Combined, n
1 NR 1 Liver failure chest infection
2 NR 1 Liver failure ischaemic bowel In-hospital
3 CRHM 1 2 Bacteraemia
4 CRHM 2 4 Chest infection
5 HCC 1 Percutaneous drainage of liver and pelvic abscesses
6 CRHM 2 Chest infection
7 CRHM 4 4 Chest infection urinary tract infection
8 CRHM 9 Chest infection
9 IHC 1 Percutaneous drainage of fluid collection 90-day
10 CRHM 4 Seroma aspirated
11 HCC 2 Postoperative haemorrhage
12 CRHM 6 Percutaneous drainage of fluid collection
13 HCC 3 3 Wound infection 90-day
14 HCC 3 Ascites controlled with diuretics
15 CRHM 3 Cardiac arrhythmia
16 NR 1 Percutaneous drainage of fluid collection
17 HCC 1 ARDS
18 Other 1 Chest infection, wound infection
19 HCC 1 NR In-hospital
NR, data not recorded; CRHM, colorectal hepatic metastases; HCC, hepatocellular carcinoma; IHC, intrahepatic cholangiocarcinoma; ARDS, adult
respiratory distress syndrome.
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at achieving complete hepatic tumour clearance.25 For patients
with advanced CRHMwho do notmeet resection criteria, thermal
ablation also provides a low-morbidity treatment option that
facilitates better survival than chemotherapy alone.26
Although ablative modalities have become an essential compo-
nent of the liver-directed therapy arsenal, the inability to consis-
tently predict the exact size and shape of the ablation zone limits
their efficacy. Radiofrequency ablation, the most commonly used
ablation modality, is particularly susceptible to this inconsistency
as it requires the flow of an electrical current, which can be
diverted away from the target tissue if a path of lower impedance
is present; this is termed ‘electrical sink’. Similarly, when RFA is
employed near large blood vessels, blood flow can divert thermal
energy away from the targeted tissue in a process termed ‘heat
sink’.2–5 Complete tumour eradication with RFA often requires
multiple treatment sessions, probably because of the technical
limitations described above.18,27 Furthermore, a recent meta-
analysis of RFA for hepatic lesions has shown that local recurrence
rates of HCC and CRHM are as high as 14.9%, again indicating
that these technical limitationsmay lead to the under-treatment of
tumours.27
Microwave technology differs fundamentally from radiofre-
quency technology and may address the shortcomings of RFA.1
Microwave ablation does not rely upon a flow of electrical current
as in RFA; rather,microwave energy is broadcast from the ablation
antenna to create an electromagnetic field within the surrounding
tissue.Water molecules within this field oscillate rapidly in accor-
dance with the microwave frequency, causing molecular friction
and a rapid rise in thermal energy throughout the field.6 The result
is a homogeneous, larger and more predictable ablation zone in
which distortion by the heat sink effect is limited.5,28,29 Direct
comparisons of percutaneous MWA and RFA in the treatment of
HCC have demonstrated lower local recurrence rates for
MWA.30–32
Another major limitation of RFA refers to the time required for
individual applications, as well as the length of overall ablation
time. Because RFA relies on current flow, rapid heating will cause
charring of tissue and heating to temperatures > 100 °C will cause
tissue water immediately adjacent to the RFA probe to boil, both
of which events result in increased tissue impedance and either the
overheating of the probe or the diminishing of the ablation zone.1
Hence, RFA requires a controlled increase in temperature and
prolonged ablation times (routinely > 10 min per application),
despite multiple innovations intended to control probe and tissue
temperature.33,34 By contrast, the properties of MWA allow for a
rapid increase in temperature throughout the microwave field
without the concern of increased impedance, which, in turn,
results in a much shorter application time.6 In addition, the
current requirement of RFA does not allow for the simultaneous
treatment of multiple lesions. Conversely,MWA allows for the use
of multiple antennae, which enables lesions to be treated in par-
allel rather than in series, thus greatly reducing operative time in
some cases.
This multi-institution, international, web-based database of
uses of MWA administered with the Microsulis 2.45-GHz Acculis
V generator with a 5-mm antenna provides important informa-
tion regarding intraoperative variables and perioperative morbid-
ity and mortality, although conclusions on the completeness of
ablation and recurrence are limited.
Most previously reported data regarding MWA outcomes
derive from single-institution reviews, in which patient- and
surgeon-related variability may be limited.7–11 This is the first
international collaborative effort to evaluate outcomes of MWA,
incorporating multiple institutions and surgeons, as well as widely
variable tumour aetiologies.
The operative details provided in this study demonstrate that
this MWA system is routinely employed for multiple ablations as
well as in concert with resection to treat a wide range of tumour
types. The advantages provided by this system are evident in the
short total ablation time per tumour (median: 4 min/tumour)
and the low number of applications required to treat each tumour
(over 50% can be treated with one application and over 75% can
be treated with two applications). Clearly, its shorter ablation time
gives MWA an advantage over other thermal ablation modalities
by allowing for the rapid simultaneous ablation of multiple
tumours, as well as for combined resection and ablation, which is
often precluded by prolonged ablation times.
The manner in which this system was employed varied con-
siderably in this study, probably as a result of the respective sur-
geons’ assessments of energy requirements for complete ablation
and their judgements of the potential for damage to adjacent
structures. Over 20% of ablations were performed at a power
setting below the standard 100 W and the range of total ablation
time per tumour varied from 30 s to 30 min. The extent of tissue
coagulation obtained with any thermal ablation system varies
significantly depending upon the type of technology, as well as
the generator and antenna design; therefore, in order to provide
an estimation of ablation volume at any given power and time
setting, each system requires thorough preclinical evaluation.35,36
This MWA system has been validated in a variety of tissue types
and at a variety of power and time settings in animal studies.37,38
However, the full range of acceptable variations in power and
time in a clinical setting remains to be defined. Extreme varia-
tions from the tested power and time settings may result in
under-treatment and should be carefully considered. Unfortu-
nately, this dataset does not allow for a more in-depth analysis of
the relationship between power and time settings and local
recurrence at each individual ablation site. It was observed,
however, that both incomplete ablations occurred at tumour
sites that were treated with the recommended 100-W power
setting for 8 min.
This MWA system utilizing a 5-mm diameter antenna is
designed for operative, rather than percutaneous, ablation. All
MWAs included in this dataset were operative: nearly 20% of
patients underwent concomitant liver resection and 40% of
patients underwent MWA of multiple lesions; thus this case mix
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differs significantly from those of many of the larger series
employing percutaneous MWA.10,31,32,39 The operative mortality
rate of 1.9% and major morbidity rate of 8.3% in this setting
appear to be comparable with those of single-institution series
with comparable case mixes.9,11 One noteworthy major compli-
cation that has not been reported in prior series was the devel-
opment of adult respiratory distress syndrome in one patient
with HCC treated with MWA, which may have resulted from a
concomitant fresh frozen plasma transfusion. Also important is
the lack of certain complications thought to be specific to MWA,
such as adjacent organ injury, skin burn at the antenna track and
hepatic vein thrombosis.
The data presented in this study represent an important
start in documenting the patterns of use, safety and efficacy of
this MWA system as used in liver-directed therapy; however,
several limitations to the study must be considered. Firstly, this
database includes only patients treated in an operative setting
with one type of MWA generator and one ablation antenna
design; therefore, these results should not be generalized to all
MWA procedures. Secondly, this multi-institution database con-
sists of self-reported data, and the degree of access afforded to
patient charts and imaging was institution-specific. Moreover,
the voluntary nature of this study resulted in incomplete data
collection, rendering some comparisons difficult, particularly
when assessing follow-up imaging. This lack of information
regarding disease status within a month of ablation for all
patients made the confirmation of ablation success difficult and
detracted from the potential benefit of this data collection
system.
A solution to this problem would be to establish a single com-
prehensive data model in which incomplete data entry is limited
by designating personnel at each centre to ensure thorough data
capture. Alternatively, a prospective multi-institution trial with
centralized imaging analysis and data collection would be
advantageous.
Despite the limitations of this data collection model, the
analysis of these multi-institution data does provide important
information regarding the patterns of use, safety and efficacy of
this MWA system as it is currently used clinically around the
world. In summary, these data demonstrate that operative MWA
utilizing this Microsulis 2.45-GHz Acculis V generator with a
5-mm antenna system is being performed, often for multiple
lesions or in conjunction with hepatic resection, with a rapid
ablation time, low morbidity and mortality profile, and high
complete ablation rate for a variety of tumours across multiple
institutions. Further collaborative efforts to combine outcomes-
based data should focus on defining the ideal energy settings for
different patient and lesion characteristics, improving follow-up
imaging analysis to define recurrence rates, and investigating
longterm outcomes. A randomized controlled trial is warranted
to compare microwave technology with other ablation modali-
ties in order to further delineate its utility in treating liver
tumours.
Acknowledgements
Data collection for this study was supported by an education grant from
Microsulis Medical Ltd to the Association of Upper Gastrointestinal Surgeons
of Great Britain and Ireland (AUGIS).
The authors submit this report on behalf of all members of the International
Microwave Tumour Ablation Group (IMTAG). Data included in this analysis
were provided by the authors and by IMTAG members Jacques Belghiti, Koert
P. de Jong, Christos Dervenis, Safi Dokmak, Omar Farges, Christos Galan-
opoulos, Ellen Hagopian, Scott Helton, Derek A. O'Reilly and Ponnandai S.
Somasundar.
Conflicts of interest
DML holds stock certificates in Microsulis Medical Ltd.
References
1. Brace CL. (2009) Radiofrequency and microwave ablation of the liver,
lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol
38:135–143.
2. Kim SK, Rhim H, Kim YS, Koh BH, Cho OK, Seo HS et al. (2005) Radiof-
requency thermal ablation of hepatic tumours: pitfalls and challenges.
Abdom Imaging 30:727–733.
3. Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buczkowski AK.
(1998) Radiofrequency ablation of porcine liver in vivo: effects of blood
flow and treatment time on lesion size. Ann Surg 227:559–565.
4. Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R et al.
(2003) Influence of large peritumoral vessels on outcome of radiofre-
quency ablation of liver tumours. J Vasc Interv Radiol 14:1267–1274.
5. Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr. (2005) Radiof-
requency versus microwave ablation in a hepatic porcine model. Radiol-
ogy 236:132–139.
6. Brace CL. (2009) Microwave ablation technology: what every user should
know. Curr Probl Diagn Radiol 38:61–67.
7. Kawamoto C, Ido K, Isoda N, Hozumi M, Nagamine N, Ono K et al. (2005)
Longterm outcomes for patients with solitary hepatocellular carcinoma
treated by laparoscopic microwave coagulation. Cancer 103:985–993.
8. Jagad RB, Koshariya M, Kawamoto J, Papastratis P, Kefalourous H,
Patris V et al. (2008) Laparoscopic microwave ablation of liver tumours:
our experience. Hepatogastroenterology 55:27–32.
9. Martin RC, Scoggins CR, McMasters KM. (2010) Safety and efficacy of
microwave ablation of hepatic tumours: a prospective review of a 5-year
experience. Ann Surg Oncol 17:171–178.
10. Liang P, Wang Y, Yu X, Dong B. (2009) Malignant liver tumours: treatment
with percutaneous microwave ablation – complications among cohort of
1136 patients. Radiology 251:933–940.
11. Iannitti DA, Martin RC, Simon CJ, Hope WW, Newcomb WL, McMasters
KM et al. (2007) Hepatic tumour ablation with clustered microwave anten-
nae: the US Phase II Trial. HPB (Oxford) 9:120–124.
12. Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM, Balliol
Collaboration et al. (2009) Evaluation and stages of surgical innovations.
Lancet 374:1089–1096.
13. Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K et al.
(1994) Ultrasonically guided percutaneous microwave coagulation
therapy for small hepatocellular carcinoma. Cancer 74:817–825.
14. Simon CJ, Dupuy DE, Iannitti DA, Lu DS, Yu NC, Aswad BI et al. (2006)
Intraoperative triple antenna hepatic microwave ablation. AJR Am J
Roentgenol 187:333–340.
584 HPB
HPB 2011, 13, 579–585 © 2011 International Hepato-Pancreato-Biliary Association
15. Llovet JM, Burroughs A, Bruix J. (2003) Hepatocellular carcinoma. Lancet
362:1907–1917.
16. Bruix J, Sherman M. (2005) Management of hepatocellular carcinoma.
Hepatology 42:1208–1236.
17. Sindram D, Lau KN, Martinie JB, Iannitti DA. (2010) Hepatic tumour
ablation. Surg Clin North Am 90:863–876.
18. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J et al. (2005)
Early-stage hepatocellular carcinoma in patients with cirrhosis: longterm
results of percutaneous image-guided radiofrequency ablation. Radiol-
ogy 234:961–967.
19. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C et al. (2008)
Sustained complete response and complications rates after radiofre-
quency ablation of very early hepatocellular carcinoma in cirrhosis: is
resection still the treatment of choice? Hepatology 47:82–89.
20. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Lerace T, Solbiati L et al.
(2000) Hepatocellular carcinoma: radio-frequency ablation of medium
and large lesions. Radiology 214:761–768.
21. Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y et al. (2005)
Percutaneous radiofrequency ablation for hepatocellular carcinoma. An
analysis of 1000 cases. Cancer 103:1201–1209.
22. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al. (2006) A
prospective randomized trial comparing percutaneous local ablative
therapy and partial hepatectomy for small hepatocellular carcinoma. Ann
Surg 243:321–328.
23. Lu MD, Kuang M, Liang LJ, Xie XY, Peng BG, Lui GJ et al. (2006) [Surgical
resection versus percutaneous thermal ablation for early-stage hepato-
cellular carcinoma: a randomized clinical trial.] Zhonghua Yi Xue Za Zhi
86:801–805.
24. Livraghi T. (2010) Single HCC smaller than 2 cm: surgery or ablation:
interventional oncologist's perspective. J Hepatobiliary Pancreat Sci
17:425–429.
25. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. (2006)
Improving resectability of hepatic colorectal metastases: expert consen-
sus statement. Ann Surg Oncol 13:1271–1280.
26. Siperstein AE, Berber E, Ballem N, Parikh RT. (2007) Survival after radiof-
requency ablation of colorectal liver metastases: 10-year experience. Ann
Surg 246:559–565; discussion 565–567.
27. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. (2005)
Local recurrence after hepatic radiofrequency coagulation: multivariate
meta-analysis and review of contributing factors. Ann Surg 242:158–
171.
28. Simon CJ, Dupuy DE, Mayo-Smith WW. (2005) Microwave ablation:
principles and applications. Radiographics 25 (Suppl. 1):69–83.
29. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. (2008) Micro-
wave liver ablation: influence of hepatic vein size on heat-sink effect in a
porcine model. J Vasc Interv Radiol 19:1087–1092.
30. Bhardwaj N, Strickland AD, Ahmad F, Dennison AR, Lloyd DM. (2010)
Liver ablation techniques: a review. Surg Endosc 24:254–265.
31. Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M et al. (2005) Percu-
taneous microwave and radiofrequency ablation for hepatocellular carci-
noma: a retrospective comparative study. J Gastroenterol 40:1054–1060.
32. Xu HX, Xie XY, Lu MD, Chen JW, Yin XY, Xu ZF et al. (2004) Ultrasound-
guided percutaneous thermal ablation of hepatocellular carcinoma using
microwave and radiofrequency ablation. Clin Radiol 59:53–61.
33. Hope WW, Arru JM, McKee JQ, Vrochides D, Aswad B, Simon CJ et al.
(2007) Evaluation of multiprobe radiofrequency technology in a porcine
model. HPB (Oxford) 9:363–367.
34. Solazzo SA, Ahmed M, Liu Z, Hines-Peralta AU, Goldberg SN. (2007)
High-power generator for radiofrequency ablation: larger electrodes and
pulsing algorithms in bovine ex vivo and porcine in vivo settings. Radiol-
ogy 242:743–750.
35. Hope WW, Schmelzer TM, Newcomb WL, Heath JJ, Lincourt AE, Norton
HJ et al. (2008) Guidelines for power and time variables for microwave
ablation in a porcine liver. J Gastrointest Surg 12:463–467.
36. Hope WW, Schmelzer TM, Newcomb WL, Heath JJ, Lincourt AE, Norton
HJ et al. (2009) Guidelines for power and time variables for microwave
ablation in an in vivo porcine kidney. J Surg Res 153:263–267.
37. Hines-Peralta AU, Pirani N, Clegg P, Cronin N, Ryan TP, Liu Z et al. (2006)
Microwave ablation: results with a 2.45-GHz applicator in ex vivo bovine
and in vivo porcine liver. Radiology 239:94–102.
38. Awad MM, Devgan L, Kamel IR, Torbensen M, Choti MA. (2007) Micro-
wave ablation in a hepatic porcine model: correlation of CT and histo-
pathologic findings. HPB (Oxford) 9:357–362.
39. Boutros C, Somasundar P, Garrean S, Saied A, Espat NJ. (2010) Micro-
wave coagulation therapy for hepatic tumours: review of the literature and
critical analysis. Surg Oncol 19:22–32.
HPB 585
HPB 2011, 13, 579–585 © 2011 International Hepato-Pancreato-Biliary Association
